Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide corresponding to the 3rd cytoplasmic loop.|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS, pH 7.7|
|Contains||0.01% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
OPA1-15577 detects GPR55 from human samples.
OPA1-15577 has been successfully used in immunohistochemistry procedures. By immunohistochemistry, OPA1-15577 detects GPR55 in formalin fixed, paraffin embedded human tissues.
The OPA1-15577 immunogen is a synthetic peptide corresponding to the 3rd cytoplasmic loop.
GPR55 has been reported to be expressed in the brain, where mRNA transcripts were detected in the caudate nucleus and putamen, but not in five other brain regions (Sawzdargo et al., 1999). ESTs have been isolated from liver/spleen libraries.
G-protein Coupled Receptors (GPCRs) comprise one of the largest families of signaling molecules with more than a thousand members currently predicted to exist. All GPCRs share a structural motif consisting of seven membrane-spanning helices, and exist in both active and inactive forms. An array of activating ligands participate in the conformation of GPCRs which leads to signaling via G-proteins and downstream effectors. Ongoing studies have also shown the vast series of reactions which participate in the negative regulation of GPCRs. This "turn-off" activity has tremendous implications for the physiological action of the cell, and continues to drive pharmacological research for new drug candidates. Two blockbuster drugs which have been developed as GPCR-targeted pharmaceuticals are Zyprexa (Eli Lilly) and Claritin (Schering-Plough) which have multi-billion dollar shares of the mental health and allergy markets, respectively.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.